157 related articles for article (PubMed ID: 20933338)
21. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
22. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
23. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade P; Vyas S; Javoy-Agid F; Herrero MT; Michel PP; Marquez J; Mouatt-Prigent A; Ruberg M; Hirsch EC; Agid Y
Histol Histopathol; 1997 Jan; 12(1):25-31. PubMed ID: 9046040
[TBL] [Abstract][Full Text] [Related]
25. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
McRitchie DA; Cartwright HR; Halliday GM
Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
[TBL] [Abstract][Full Text] [Related]
26. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C
J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435
[TBL] [Abstract][Full Text] [Related]
27. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Locke CJ; Fox SA; Caldwell GA; Caldwell KA
Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
[TBL] [Abstract][Full Text] [Related]
28. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
29. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
31. [Inflammation and Parkinson's disease].
Barcia González C; Herrero Ezquerro MT
Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
[TBL] [Abstract][Full Text] [Related]
32. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
33. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
34. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J
J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674
[TBL] [Abstract][Full Text] [Related]
35. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C
Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469
[TBL] [Abstract][Full Text] [Related]
36. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
Nagel F; Bähr M; Dietz GP
Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215
[TBL] [Abstract][Full Text] [Related]
38. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
Sulzer D
Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
[TBL] [Abstract][Full Text] [Related]
39. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Mocchetti I; Bachis A; Nosheny RL; Tanda G
Neurotox Res; 2007 Sep; 12(2):135-43. PubMed ID: 17967737
[TBL] [Abstract][Full Text] [Related]
40. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Li LH; Qin HZ; Wang JL; Wang J; Wang XL; Gao GD
J Int Med Res; 2009; 37(2):455-63. PubMed ID: 19383240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
